ArticleBMC infectious diseases2026
A study on antibody persistence following severe fever with thrombocytopenia syndrome virus infection in the Dabie Mountain Region, China.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo characterize the duration and determinants of SFTSV-specific antibody persistence following natural infection, informing vaccine development for severe fever with thrombocytopenia syndrome (SFTS).
methodsWe conducted a retrospective cohort study among 463 convalescent SFTS patients in the Dabie Mountains, a hyperendemic region in China. Using illness onset dates and a single post-infection serum sample per participant, we reconstructed individual follow-up durations and applied Kaplan-Meier survival analysis and Cox proportional hazards models to assess time to seroreversion and its determinants.
resultsSeropositivity declined with longer time since illness onset. Age was significantly associated with antibody persistence: individuals aged ≥ 70 years showed the most rapid antibody waning, whereas those aged < 50 years showed longer detectable IgG persistence. Geographic location was also associated with durability. Compared with patients from Huoqiu County (predominantly plain terrain), those from mountainous/hilly areas had lower risks of antibody loss-Yu'an District (HR 0.060 [95%CI 0.014-0.262]) Jinzhai County(HR 0.358 [95%CI 0.202-0.635]) and Huoshan County(HR 0.390 [95%CI 0.195-0.780]).
conclusionSFTSV-specific IgG antibodies persist for several years in most survivors, with longer duration observed in younger individuals and residents of highland endemic foci. These findings suggest that of age and geography in shaping post-infection immunity and support tailored vaccination and surveillance strategies in heterogeneous transmission settings. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.